卡维地洛对冠心病患者血浆氧化修饰低密度脂蛋白的影响

Effect of Carvedilol on Plasma Oxidatively Modified Low Density Lipoprotein in Patients with Coronary Heart Disease

目的 :观察临床应用卡维地洛能否降低冠心病患者血浆氧化修饰低密度脂蛋白 (Ox LDL)水平。方法 :选择确诊冠心病患者及年龄、性别相匹配的正常对照组各 30例。冠心病组卡维地洛平均用量为 (10± 2 .5 )mg/d ,共 4个月 ,于服药前、服药后2个月及 4个月 ,分别采集清晨空腹血 ,以检测Ox LDL ,丙二醛 (MDA)。结果 :冠心病组的Ox LDL、MDA水平显著高于对照组 ,在用药后 2及 4个月冠心病组Ox LDL较用药前有显著降低 (P <0 .0 5 ) ,MDA显示出类似的趋势 (P <0 .0 1)。结论 :卡维地洛具有抗氧化作用 ,可以降低冠心病患者血浆Ox LDL水平。

Objective: To evaluate the antioxidant effect of carvedilol on decreasing the Ox LDL level in patients with coronary heart disease(CHD). Methods: Thirty CHD patients and thirty sex and age-matched normal controls were selected. The patients were administered with carvidilol in a close of 10±2.5mg/day for 4 months.The morning venous blood was collected to determine the Ox-LDL and the malondiadenyde before administration and 2,4 months after administation. Results: The levels of Ox-LDL and MDA of patients group were significantly higher than those of the controls.The Ox-LDL levels after 2 and 4 months of the administration were declined significantly compared with before adminstration (47.20±19.46 vs 58.54±24.88, P<0.05; 44.76±20.47 vs 58.54±24.88, P<0.05), the MDA level changed in a similar trend.(7.17±2.71 vs 9.79±3.65,P<0.01; 5.75±2.88 vs 9.79±3.65, P<0.01). Conclusion:Carvedilol may carry out antioxidant effect on dlcreasing the plasma level of Ox-LDL in CHD patients.